Based on the key indicators related to Atossa Genetics' liquidity, profitability, solvency, and operating efficiency, Atossa Genetics may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At this time, Atossa Genetics' Other Assets are comparatively stable compared to the past year. Common Stock Total Equity is likely to gain to about 27.5 M in 2025, whereas Short and Long Term Debt Total is likely to drop slightly above 15.4 K in 2025. Key indicators impacting Atossa Genetics' financial strength include:
Investors should never underestimate Atossa Genetics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Atossa Genetics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Atossa Genetics.
Understanding current and past Atossa Genetics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Atossa Genetics' financial statements are interrelated, with each one affecting the others. For example, an increase in Atossa Genetics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Atossa Genetics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Atossa Genetics. Check Atossa Genetics' Beneish M Score to see the likelihood of Atossa Genetics' management manipulating its earnings.
Atossa Genetics Stock Summary
Atossa Genetics competes with Ocugen, Jaguar Animal, Tonix Pharmaceuticals, Traws Pharma, and Senseonics Holdings. Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington. Atossa Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 6 people.
The reason investors look at the income statement is to determine what Atossa Genetics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Atossa Genetics's current stock value. Our valuation model uses many indicators to compare Atossa Genetics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Atossa Genetics competition to find correlations between indicators driving Atossa Genetics's intrinsic value. More Info.
Atossa Genetics is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . At this time, Atossa Genetics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Atossa Genetics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Atossa Genetics Systematic Risk
Atossa Genetics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Atossa Genetics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Atossa Genetics correlated with the market. If Beta is less than 0 Atossa Genetics generally moves in the opposite direction as compared to the market. If Atossa Genetics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Atossa Genetics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Atossa Genetics is generally in the same direction as the market. If Beta > 1 Atossa Genetics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Atossa Genetics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Atossa Genetics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Atossa Genetics growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Atossa Genetics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Atossa Genetics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Atossa Genetics based on widely used predictive technical indicators. In general, we focus on analyzing Atossa Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Atossa Genetics's daily price indicators and compare them against related drivers.
When running Atossa Genetics' price analysis, check to measure Atossa Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atossa Genetics is operating at the current time. Most of Atossa Genetics' value examination focuses on studying past and present price action to predict the probability of Atossa Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atossa Genetics' price. Additionally, you may evaluate how the addition of Atossa Genetics to your portfolios can decrease your overall portfolio volatility.